Talk:New Article Requests

Before You Submit a Proposal

• EVALUATION CRITERIA: Review these to be sure your proposal is eligible.
• EXISTING ARTICLES: Review these to see if your proposed topic is already included or could be inlcuded in an existing EyeWiki article. You can do this by performing a thorough search using various related key terms.
  • If you find a pre-existing stand-alone article that addresses your topic or an article that includes your topic please edit the article to include your own input. You will be automatically recognized as a contributor to that article.
  • Of those proposals that are not accepted, 85% are rejected because the topic is already covered or could be covered in an existing EyeWiki article.
• PROPOSALS PREVIOUSLY SUBMITTED: Review these and please do not resubmit these topics.

Instructions

• IMPORTANT: Review the section above "Before You Submit a Proposal"
• Click the "Add topic" link to create a new proposal on this page
• Then add the relevant list items as shown
  • Title: Enter this in the Subject field
  • Summary: Please provide some details about what will be covered and why you think the article would benefit EyeWiki. Do not submit a complete article.
  • Section: Indicate what subspecialty section the article should be added to. You may indicate up to 2 sections.
  • Submitted by: Name of the ophthalmologist submitting the proposal. Sign and date your request by entering 4 tilde ~ characters only. This will automatically add your username, a time stamp and a link to your profile. You will see this after you save the page.
    • SAMPLE: Rayna.Ungersma.AAO (talk) 10:01, April 30, 2024 (PDT)
• Click: SAVE at the bottom of the page

Sample Proposal

Biosimilars in Ophthalmology Summary: Patents for original biologics used to treat nAMD and DME are approaching expiration. Numerous companies are striving to replicate these biologics as biosimilars, which are drugs that mimic the effects of the original biologic, but do not have the same active ingredients. This article will summarize the current literature about biosimilars and their safety, efficacy, and quality and provide an in-depth review of approved biosimilars as well as those that are in development. This article will provide EyeWiki readers with information about numerous alternatives for treatment nAMD and DME.
Section: Retina/Vitreous
Submitted by: Rayna.Ungersma.AAO (talk) 15:04, May 1, 2024 (PDT)

Ocular Manifestations of Vaccine-Preventable Diseases

With the rise of vaccine hesitancy, ophthalmologists must be aware of the ocular manifestations of vaccine-preventable diseases, as delayed recognition can lead to significant morbidity. This article will provide a comprehensive review of vaccine-preventable diseases with ocular involvement. By highlighting the critical role of immunization in safeguarding ocular health, this article will serve as a valuable resource for EyeWiki readers seeking to better understand and counsel patients on the ophthalmic risks of vaccine-preventable infections. Section: Uveitis Submitted by: Kayne.McCarthy (talk)

Familial LCAT deficiency and fish-eye disease

Bilateral stromal corneal opacifications are important clinical findings that may indicate underlying systemic diseases. Fish eye disease, also known as partial lecithin–cholesterol acyltransferase (LCAT) deficiency, is named for the corneal appearance resembling that of boiled fish. Unlike total LCAT deficiency, fish eye disease does not cause anemia or renal failure. Familial LCAT deficiency is a rare autosomal recessive disorder of cholesterol metabolism caused by LCAT gene mutations. It is characterized by extremely low high-density lipoprotein (HDL) levels and systemic manifestations, including corneal opacification, hemolytic anemia, and chronic kidney disease.

Section: Cornea/External Disease Submitted by: Joao.Mendes (talk) 2025-03-22T06:23:23‎

Robotic-Assisted Vitreoretinal Surgery

Summary: Robotic-assisted vitreoretinal surgery is an emerging technology designed to enhance precision and stability in delicate intraocular procedures. By minimizing surgeon tremor and enabling micrometer-level movements, robotic platforms allow for safer and more controlled interventions, particularly in tasks such as subretinal drug delivery, epiretinal membrane peeling, and gene therapy applications. Early clinical trials and real-world cases have demonstrated improved surgical accuracy, potentially expanding the boundaries of what is achievable in vitreoretinal surgery. However, challenges such as cost, accessibility, and integration into routine practice remain areas of ongoing research.

Section: Retina/Vitreous

Submitted by: Hashem.AbuSerhan (talk) 08:39, March 22, 2025 (PDT)